DarioHealth Corp.

For the period ended Dec 31, 2025. Filed Mar 19, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 19, 2026

DRIO$2.39+16.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Comprehensive Loss


· · Year ended
· · December 31,
· · 2025 · · 2024
Revenues:
Services	$14,929	$20,197
Consumer hardware	7,430	6,843
Total revenues	22,359	27,040

Cost of revenues:
Services	2,900	3,606
Consumer hardware	5,124	5,139
Amortization of acquired intangible assets	1,670	5,028
Total cost of revenues	9,694	13,773

Gross profit	12,665	13,267

Operating expenses:
Research and development	$13,791	$24,179
Sales and marketing	20,338	26,350
General and administrative	15,191	20,482

Total operating expenses	49,320	71,011

Operating loss	36,655	57,744

Interest expenses	3,020	—
Other financial expenses (income), net	1,934	(13,145)

Total financial expenses (income), net	4,954	(13,145)

Loss before taxes	41,609	44,599

Income taxes (benefit)	105	(1,852)

Net loss	$41,714	$42,747

Deemed dividend (contribution)	$20,021	$(1,765)

Net loss attributable to common shareholders	$61,735	$40,982

Net loss per share:

Basic and diluted loss per share of common stock	$10.12	$12.27
Weighted average number of common stock used in computing basic and diluted net loss per share**	3,982,956	2,451,971

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.